# OnCo record rejuv-second-topoisomerase-inhibitors-short-latency (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/rejuv-second-topoisomerase-inhibitors-short-latency/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "rejuv-second-topoisomerase-inhibitors-short-latency" ;
  schema:name "Topoisomerase II inhibitors and the shorter latency"@en ;
  schema:alternateName "Etoposide-related leukaemia"@en, "11q23 therapy-related leukaemia"@en, "KMT2A-rearranged secondary AML"@en ;
  schema:description "Etoposide and the anthracyclines can cause a leukaemia too, but a different one: it arrives after about two years rather than six, it starts as acute leukaemia without a myelodysplastic phase, and it carries a balanced break in a chromosome rather than a missing piece. So the first two or three years after this chemotherapy are when a blood count matters most."@en ;
  schema:url <https://onco.cc/terms/rejuv-second-topoisomerase-inhibitors-short-latency/> ;
  schema:dateModified "2026-10-02"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Topoisomerase_inhibitor> ;
  schema:citation <https://doi.org/10.1182/blood-2002-11-3343>, <https://doi.org/10.1038/sj.leu.2405078>, <https://doi.org/10.3324/haematol.11034>, <https://doi.org/10.1001/jamaoncol.2018.5625> ;
  onco:tag "rejuvenation", "survivorship", "second-cancers", "blood", "chemotherapy" ;
  onco:related <https://onco.cc/terms/rejuv-second-cancers-overview/>, <https://onco.cc/terms/rejuv-second-alkylating-agents-and-myeloid-neoplasms/>, <https://onco.cc/terms/rejuv-second-from-clone-to-disease/> ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/aml-secondary/>, <https://onco.cc/cancers/mds/>, <https://onco.cc/cancers/testicular/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/rejuvenation/>, <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/survivorship-care-plan/> ;
  onco:drugs <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/doxorubicin/> ;
  onco:terms <https://onco.cc/terms/secondary-malignancy/>, <https://onco.cc/terms/late-effects/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-survivorship/> .